Cinpanemab (BIIB054) 是一种人源单克隆抗体，可与 α-突触核蛋白 1-10 位残基结合。Cinpanemab 可用于研究帕金森病。
| 生物活性 | Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds toα-synuclein. Cinpanemab can be used for the research of Parkinson's disease[1][2]. |
| IC50& Target | |
体外研究
(In Vitro) | Cinpanemab 对聚合形式的 α-syn 具有高度选择性，对纤维状重组 α-syn 的表观亲和力至少比单体重组 α-syn 高 800 倍，并且对人 PD 脑组织有强烈的偏好[2]。
|
体内研究
(In Vivo) | Cinpanemab (30 mg/kg; 腹腔注射) 改善 α-syn PFF 接种小鼠模型中的 PD 样表型[2]。
| Animal Model: | C57BL/6JRccHsd WT mice, transgenic M83 mice expressing human α-syn A53T, and transgenic bacterial artificial chromosome mice expressing human α-syn A53T were anesthetized and stereotaxically injected with α-syn preformed fibrils (PFFs) into the right forebrain[2] | | Dosage: | 30 mg/kg | | Administration: | Intraperitoneal (i.p.) injections 2-3 times prior to α-syn PFF injection and weekly post-injection until time of sacrifice | | Result: | Attenuated the spreading of α-syn pathology, rescued motor impairments, and reduced the loss of dopamine transporter density in dopaminergic terminals in striatum. |
|
| CAS 号 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com